259 related articles for article (PubMed ID: 27876874)
21. Nuclear orphan receptor NR2F6 confers cisplatin resistance in epithelial ovarian cancer cells by activating the Notch3 signaling pathway.
Li H; Zhang W; Niu C; Lin C; Wu X; Jian Y; Li Y; Ye L; Dai Y; Ouyang Y; Chen J; Qiu J; Song L; Zhang Y
Int J Cancer; 2019 Oct; 145(7):1921-1934. PubMed ID: 30895619
[TBL] [Abstract][Full Text] [Related]
22. Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells.
Momeny M; Zarrinrad G; Moghaddaskho F; Poursheikhani A; Sankanian G; Zaghal A; Mirshahvaladi S; Esmaeili F; Eyvani H; Barghi F; Sabourinejad Z; Alishahi Z; Yousefi H; Ghasemi R; Dardaei L; Bashash D; Chahardouli B; Dehpour AR; Tavakkoly-Bazzaz J; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Sci Rep; 2017 Jun; 7(1):4204. PubMed ID: 28646172
[TBL] [Abstract][Full Text] [Related]
23. Identification of Sox6 as a regulator of pancreatic cancer development.
Jiang W; Yuan Q; Jiang Y; Huang L; Chen C; Hu G; Wan R; Wang X; Yang L
J Cell Mol Med; 2018 Mar; 22(3):1864-1872. PubMed ID: 29369542
[TBL] [Abstract][Full Text] [Related]
24. Lipocalin-2 negatively modulates the epithelial-to-mesenchymal transition in hepatocellular carcinoma through the epidermal growth factor (TGF-beta1)/Lcn2/Twist1 pathway.
Wang YP; Yu GR; Lee MJ; Lee SY; Chu IS; Leem SH; Kim DG
Hepatology; 2013 Oct; 58(4):1349-61. PubMed ID: 23696034
[TBL] [Abstract][Full Text] [Related]
25. A critical role of Oct4A in mediating metastasis and disease-free survival in a mouse model of ovarian cancer.
Samardzija C; Luwor RB; Volchek M; Quinn MA; Findlay JK; Ahmed N
Mol Cancer; 2015 Aug; 14():152. PubMed ID: 26260289
[TBL] [Abstract][Full Text] [Related]
26. Ursolic acid inhibits proliferation and reverses drug resistance of ovarian cancer stem cells by downregulating ABCG2 through suppressing the expression of hypoxia-inducible factor-1α in vitro.
Wang WJ; Sui H; Qi C; Li Q; Zhang J; Wu SF; Mei MZ; Lu YY; Wan YT; Chang H; Guo PT
Oncol Rep; 2016 Jul; 36(1):428-40. PubMed ID: 27221674
[TBL] [Abstract][Full Text] [Related]
27. HMGA2 regulates epithelial-mesenchymal transition and the acquisition of tumor stem cell properties through TWIST1 in gastric cancer.
Li W; Wang Z; Zha L; Kong D; Liao G; Li H
Oncol Rep; 2017 Jan; 37(1):185-192. PubMed ID: 27878307
[TBL] [Abstract][Full Text] [Related]
28. ZEB1 Promotes Chemoresistance to Cisplatin in Ovarian Cancer Cells by Suppressing SLC3A2.
Cui Y; Qin L; Tian D; Wang T; Fan L; Zhang P; Wang Z
Chemotherapy; 2018; 63(5):262-271. PubMed ID: 30481785
[TBL] [Abstract][Full Text] [Related]
29. Highly expressed NRSN2 is related to malignant phenotype in ovarian cancer.
Tang W; Ren A; Xiao H; Sun H; Li B
Biomed Pharmacother; 2017 Jan; 85():248-255. PubMed ID: 27908706
[TBL] [Abstract][Full Text] [Related]
30. A ROS/STAT3/HIF-1α signaling cascade mediates EGF-induced TWIST1 expression and prostate cancer cell invasion.
Cho KH; Choi MJ; Jeong KJ; Kim JJ; Hwang MH; Shin SC; Park CG; Lee HY
Prostate; 2014 May; 74(5):528-36. PubMed ID: 24435707
[TBL] [Abstract][Full Text] [Related]
31. Twist1 induces endothelial differentiation of tumour cells through the Jagged1-KLF4 axis.
Chen HF; Huang CH; Liu CJ; Hung JJ; Hsu CC; Teng SC; Wu KJ
Nat Commun; 2014 Aug; 5():4697. PubMed ID: 25146389
[TBL] [Abstract][Full Text] [Related]
32. CXCL11 mediates TWIST1-induced angiogenesis in epithelial ovarian cancer.
Koo YJ; Kim TJ; Min KJ; So KA; Jung US; Hong JH
Tumour Biol; 2017 May; 39(5):1010428317706226. PubMed ID: 28488542
[TBL] [Abstract][Full Text] [Related]
33. Targeting TWIST1 through loss of function inhibits tumorigenicity of human glioblastoma.
Mikheev AM; Mikheeva SA; Severs LJ; Funk CC; Huang L; McFaline-Figueroa JL; Schwensen J; Trapnell C; Price ND; Wong S; Rostomily RC
Mol Oncol; 2018 Jun; 12(7):1188-1202. PubMed ID: 29754406
[TBL] [Abstract][Full Text] [Related]
34. EMT-associated up-regulation of L1CAM provides insights into L1CAM-mediated integrin signalling and NF-κB activation.
Kiefel H; Bondong S; Pfeifer M; Schirmer U; Erbe-Hoffmann N; Schäfer H; Sebens S; Altevogt P
Carcinogenesis; 2012 Oct; 33(10):1919-29. PubMed ID: 22764136
[TBL] [Abstract][Full Text] [Related]
35. HCRP1 downregulation promotes hepatocellular carcinoma cell migration and invasion through the induction of EGFR activation and epithelial-mesenchymal transition.
Xu J; Zhang X; Wang H; Ge S; Gao T; Song L; Wang X; Li H; Qin Y; Zhang Z
Biomed Pharmacother; 2017 Apr; 88():421-429. PubMed ID: 28122307
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of AKT sensitizes chemoresistant ovarian cancer cells to cisplatin by abrogating S and G2/M arrest.
Zhang D; Piao HL; Li YH; Qiu Q; Li DJ; Du MR; Tsang BK
Exp Mol Pathol; 2016 Jun; 100(3):506-13. PubMed ID: 27163202
[TBL] [Abstract][Full Text] [Related]
37. Short hairpin RNA targeting Twist1 suppresses cell proliferation and improves chemosensitivity to cisplatin in HeLa human cervical cancer cells.
Zhu K; Chen L; Han X; Wang J; Wang J
Oncol Rep; 2012 Apr; 27(4):1027-34. PubMed ID: 22245869
[TBL] [Abstract][Full Text] [Related]
38. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.
Liu M; Qi Z; Liu B; Ren Y; Li H; Yang G; Zhang Q
Oncotarget; 2015 Sep; 6(28):25281-94. PubMed ID: 26325371
[TBL] [Abstract][Full Text] [Related]
39. Knockdown of CMTM3 promotes metastasis of gastric cancer via the STAT3/Twist1/EMT signaling pathway.
Yuan W; Li T; Mo X; Wang X; Liu B; Wang W; Su Y; Xu L; Han W
Oncotarget; 2016 May; 7(20):29507-19. PubMed ID: 27121055
[TBL] [Abstract][Full Text] [Related]
40. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function.
Fraser M; Bai T; Tsang BK
Int J Cancer; 2008 Feb; 122(3):534-46. PubMed ID: 17918180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
